Potential T cell biomarkers of response to AHSCT have been reported in MS and T1D (6, 7), including the expansion of regulatory CD4 (Foxp3+CD127lo) and CD8 (CD28−CD57+ or PD-1+) T cells. This evidence concerns the gene CD4 and myeloid sarcoma.